FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204649495> ?p ?o ?g. }

• W3204649495 endingPage "497" @default.
• W3204649495 startingPage "490" @default.
• W3204649495 abstract "To describe molecular and clinical characteristics of patients with high-grade recurrent ovarian carcinoma (HGOC) who had long-term responses to the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib.This post hoc analysis pooled patients from Study 10 (NCT01482715; Parts 2A and 2B; n = 54) and ARIEL2 (NCT01891344; Parts 1 and 2; n = 491). Patients with investigator-assessed complete or partial response per RECIST were classified based on duration of response (DOR): long (≥1 year), intermediate (6 months to <1 year), or short (<6 months). Next-generation sequencing was used to detect deleterious mutations and loss of heterozygosity (LOH) in tumors.Overall, 25.3% (138/545) of enrolled patients were responders. Of these, 27.5% (38/138) had long-term responses; 28.3% (39/138) were intermediate- and 34.8% (48/138) were short-term responders. Most of the long-term responders harbored a BRCA1 or BRCA2 (BRCA) mutation (71.1%, 27/38), and BRCA structural variants were most frequent among long-term responders (14.8%; 4/27). Responders with HGOC harboring a BRCA structural variant (n = 5) had significantly longer DOR than patients with other mutation types (n = 81; median not reached vs 0.62 years; HR, 0.21; 95% CI, 0.10-0.43; unadjusted p = 0.014). Among responders with BRCA wild-type HGOC, most long- and intermediate-term responders had high genome-wide LOH: 81.8% (9/11) and 76.9% (10/13), respectively, including 7 with deleterious RAD51C, RAD51D, or CDK12 mutations.Among patients who responded to rucaparib, a substantial proportion achieved responses lasting ≥1 year. These analyses demonstrate the relationship between DOR to PARP inhibitor treatment and molecular characteristics in HGOC, such as presence of reversion-resistant BRCA structural variants." @default.
• W3204649495 created "2021-10-11" @default.
• W3204649495 creator A5002391153 @default.
• W3204649495 creator A5009234043 @default.
• W3204649495 creator A5009816218 @default.
• W3204649495 creator A5020493456 @default.
• W3204649495 creator A5021359849 @default.
• W3204649495 creator A5025155327 @default.
• W3204649495 creator A5042137756 @default.
• W3204649495 creator A5045419282 @default.
• W3204649495 creator A5053409630 @default.
• W3204649495 creator A5054370710 @default.
• W3204649495 creator A5054602117 @default.
• W3204649495 creator A5058238015 @default.
• W3204649495 creator A5064757320 @default.
• W3204649495 creator A5069918197 @default.
• W3204649495 creator A5072308451 @default.
• W3204649495 creator A5072712459 @default.
• W3204649495 creator A5078857320 @default.
• W3204649495 creator A5082234321 @default.
• W3204649495 creator A5084420374 @default.
• W3204649495 creator A5086996122 @default.
• W3204649495 creator A5088144652 @default.
• W3204649495 creator A5089242165 @default.
• W3204649495 date "2021-12-01" @default.
• W3204649495 modified "2023-10-17" @default.
• W3204649495 title "Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer" @default.
• W3204649495 cites W1781764024 @default.
• W3204649495 cites W1973268287 @default.
• W3204649495 cites W2009007206 @default.
• W3204649495 cites W2100419317 @default.
• W3204649495 cites W2106542343 @default.
• W3204649495 cites W2519148856 @default.
• W3204649495 cites W2557666746 @default.
• W3204649495 cites W2589712516 @default.
• W3204649495 cites W2593067736 @default.
• W3204649495 cites W2606696169 @default.
• W3204649495 cites W2623263876 @default.
• W3204649495 cites W2751912349 @default.
• W3204649495 cites W2754327139 @default.
• W3204649495 cites W2765304775 @default.
• W3204649495 cites W2786268518 @default.
• W3204649495 cites W2892812402 @default.
• W3204649495 cites W2901506506 @default.
• W3204649495 cites W2948947061 @default.
• W3204649495 cites W2984886575 @default.
• W3204649495 cites W3010272420 @default.
• W3204649495 cites W3043828603 @default.
• W3204649495 cites W3159728738 @default.
• W3204649495 doi "https://doi.org/10.1016/j.ygyno.2021.08.030" @default.
• W3204649495 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34602290" @default.
• W3204649495 hasPublicationYear "2021" @default.
• W3204649495 type Work @default.
• W3204649495 sameAs 3204649495 @default.
• W3204649495 citedByCount "17" @default.
• W3204649495 countsByYear W32046494952021 @default.
• W3204649495 countsByYear W32046494952022 @default.
• W3204649495 countsByYear W32046494952023 @default.
• W3204649495 crossrefType "journal-article" @default.
• W3204649495 hasAuthorship W3204649495A5002391153 @default.
• W3204649495 hasAuthorship W3204649495A5009234043 @default.
• W3204649495 hasAuthorship W3204649495A5009816218 @default.
• W3204649495 hasAuthorship W3204649495A5020493456 @default.
• W3204649495 hasAuthorship W3204649495A5021359849 @default.
• W3204649495 hasAuthorship W3204649495A5025155327 @default.
• W3204649495 hasAuthorship W3204649495A5042137756 @default.
• W3204649495 hasAuthorship W3204649495A5045419282 @default.
• W3204649495 hasAuthorship W3204649495A5053409630 @default.
• W3204649495 hasAuthorship W3204649495A5054370710 @default.
• W3204649495 hasAuthorship W3204649495A5054602117 @default.
• W3204649495 hasAuthorship W3204649495A5058238015 @default.
• W3204649495 hasAuthorship W3204649495A5064757320 @default.
• W3204649495 hasAuthorship W3204649495A5069918197 @default.
• W3204649495 hasAuthorship W3204649495A5072308451 @default.
• W3204649495 hasAuthorship W3204649495A5072712459 @default.
• W3204649495 hasAuthorship W3204649495A5078857320 @default.
• W3204649495 hasAuthorship W3204649495A5082234321 @default.
• W3204649495 hasAuthorship W3204649495A5084420374 @default.
• W3204649495 hasAuthorship W3204649495A5086996122 @default.
• W3204649495 hasAuthorship W3204649495A5088144652 @default.
• W3204649495 hasAuthorship W3204649495A5089242165 @default.
• W3204649495 hasBestOaLocation W32046494952 @default.
• W3204649495 hasConcept C104317684 @default.
• W3204649495 hasConcept C121608353 @default.
• W3204649495 hasConcept C126322002 @default.
• W3204649495 hasConcept C143589142 @default.
• W3204649495 hasConcept C143998085 @default.
• W3204649495 hasConcept C180754005 @default.
• W3204649495 hasConcept C182979987 @default.
• W3204649495 hasConcept C2779138821 @default.
• W3204649495 hasConcept C2780194787 @default.
• W3204649495 hasConcept C2780427987 @default.
• W3204649495 hasConcept C54355233 @default.
• W3204649495 hasConcept C71924100 @default.
• W3204649495 hasConcept C82381507 @default.
• W3204649495 hasConcept C86803240 @default.
• W3204649495 hasConcept C90924648 @default.
• W3204649495 hasConceptScore W3204649495C104317684 @default.

• next